These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 7061662)

  • 1. High-performance liquid chromatographic analysis of the sulfide metabolite of sulfinpyrazone in plasma.
    Godbillon J; Gauron S; Gosset G
    J Chromatogr; 1982 Feb; 227(2):516-20. PubMed ID: 7061662
    [No Abstract]   [Full Text] [Related]  

  • 2. High-performance liquid chromatographic analysis of sulfinpyrazone and its metabolites in biological fluids.
    Bjornsson TD; Wolfram KM; Routledge PA; Shand DG
    J Chromatogr; 1980 Mar; 181(3-4):417-25. PubMed ID: 7391155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics and metabolism of sulfinpyrazone.
    Mahony C; Wolfram KM; Nash PV; Bjornsson TD
    Clin Pharmacol Ther; 1983 Apr; 33(4):491-7. PubMed ID: 6831828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-performance liquid chromatographic determination of sulfinpyrazone and its metabolites in plasma.
    Kuo BS; Kaplan LA; Ritschel WA
    Arzneimittelforschung; 1984; 34(5):548-50. PubMed ID: 6540568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paired-ion high-performance liquid chromatographic assay for sulfinpyrazone in plasma.
    Patel NJ; Kildsig DO; Banker GS; Mayer PR; Gonzalez MA
    J Pharm Sci; 1982 Dec; 71(12):1413-5. PubMed ID: 7153896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simple and rapid high-performance liquid chromatographic method for the analysis of sulfinpyrazone and four of its metabolites in human plasma.
    Tam YK; Ferguson SM; Yau ML; Wyse DG
    J Chromatogr; 1984 Oct; 310(2):438-44. PubMed ID: 6511862
    [No Abstract]   [Full Text] [Related]  

  • 7. Determination of sulfinpyrazone and four metabolites in plasma and urine by high pressure liquid chromatography.
    Lentjes EG; Tan Y; Van Ginneken CA
    Pharm Weekbl Sci; 1985 Dec; 7(6):252-9. PubMed ID: 4080510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state.
    Rosenkranz B; Fischer C; Jakobsen P; Kirstein Pedersen A; Frölich JC
    Eur J Clin Pharmacol; 1983; 24(2):231-5. PubMed ID: 6840173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New metabolites of sulfinpyrazone in man.
    Dieterle W; Faigle JW; Moppert J
    Arzneimittelforschung; 1980; 30(6):989-93. PubMed ID: 7191279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of sulfinpyrazone and its metabolites in human plasma and urine by high-performance liquid chromatography.
    de Vries JX; Staiger C; Wang NS; Schlicht F
    J Chromatogr; 1983 Oct; 277():408-13. PubMed ID: 6643630
    [No Abstract]   [Full Text] [Related]  

  • 11. Determination of sulfinpyrazone and two of its metabolites in human plasma and urine by gas chromatography and selective detection.
    Jakobsen P; Pedersen AK
    J Chromatogr; 1979 Jul; 163(3):259-69. PubMed ID: 541381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous determination of sulfinpyrazone and four of its metabolites by high-performance liquid chromatography.
    Jakobsen P; Pedersen AK
    J Chromatogr; 1981 May; 223(2):460-5. PubMed ID: 7251803
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites.
    He M; Kunze KL; Trager WF
    Drug Metab Dispos; 1995 Jun; 23(6):659-63. PubMed ID: 7587949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simple and rapid micro-determination of sulfinpyrazone (Anturan) in biological fluids by reversed-phase high-performance liquid chromatography.
    Wong LT; Solomonraj G; Thomas BH
    J Chromatogr; 1978 Mar; 150(2):521-6. PubMed ID: 632338
    [No Abstract]   [Full Text] [Related]  

  • 15. Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing.
    Pedersen AK; FitzGerald GA
    Clin Pharmacol Ther; 1985 Jan; 37(1):36-42. PubMed ID: 3917387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human platelet cyclo-oxygenase activity by sulfinpyrazone and three of its metabolites.
    Del Maschio A; Livio M; Cerletti C; De Gaetano G
    Eur J Pharmacol; 1984 Jun; 101(3-4):209-14. PubMed ID: 6432556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years.
    Walter E; Staiger C; de Vries J; Weber E; Bitzer W; Degott M; Jüngling K
    Klin Wochenschr; 1982 Nov; 60(22):1409-13. PubMed ID: 6129344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the gut flora in the reduction of sulfinpyrazone in humans.
    Strong HA; Oates J; Sembi J; Renwick AG; George CF
    J Pharmacol Exp Ther; 1984 Sep; 230(3):726-32. PubMed ID: 6470977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative drug elimination capacity in man-glutethimide, amobarbital, antipyrine, and sulfinpyrazone.
    Kadar D; Inaba T; Endrenyi L; Johnson GE; Kalow W
    Clin Pharmacol Ther; 1973; 14(4):552-60. PubMed ID: 4723263
    [No Abstract]   [Full Text] [Related]  

  • 20. Correlation between inhibitory effect on platelet aggregation and disposition of sulfinpyrazone and its metabolites in rabbits. Part II: Multiple dose study.
    Kuo BS; Ritschel WA
    Biopharm Drug Dispos; 1987; 8(1):11-21. PubMed ID: 3580509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.